A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #6 — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (86 Sites)
Showing the first 25 of 86 sites.
- Exelixis Clinical Site #6 — Duarte, California
- Exelixis Clinical Site #49 — La Jolla, California
- Exelixis Clinical Site #7 — Los Angeles, California
- Exelixis Clinical Site #84 — Los Angeles, California
- Exelixis Clinical Site #66 — San Francisco, California
- Exelixis Clinical Site #71 — Stanford, California
- Exelixis Clinical Site #15 — Lake Mary, Florida
- Exelixis Clinical Site #24 — Miami, Florida
- Exelixis Clinical Site #11 — Atlanta, Georgia
- Exelixis Clinical Site #80 — Atlanta, Georgia
- Exelixis Clinical Site #41 — Iowa City, Iowa
- Exelixis Clinical Site #36 — Westwood, Kansas
- Exelixis Clinical Site #62 — Scarborough, Maine
- Exelixis Clinical Site #44 — Baltimore, Maryland
- Exelixis Clinical Site #4 — Boston, Massachusetts
- Exelixis Clinical Site #45 — Ann Arbor, Michigan
- Exelixis Clinical Site #2 — Grand Rapids, Michigan
- Exelixis Clinical Site #25 — Saint Paul, Minnesota
- Exelixis Clinical Site #13 — Omaha, Nebraska
- Exelixis Clinical Site #9 — East Brunswick, New Jersey
- Exelixis Clinical Site #83 — New Brunswick, New Jersey
- Exelixis Clinical Site #86 — New York, New York
- Exelixis Clinical Site #35 — New York, New York
- Exelixis Clinical #78 — New York, New York
- Exelixis Clinical Site #85 — The Bronx, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasm Malignant
- A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer — Baton Rouge, Louisiana
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) — Tucson, Arizona
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) — Baltimore, Maryland
Explore by condition: All Neoplasm Malignant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.